PURPOSE: Sarcomatoid changes in renal cell carcinoma are associated with a poor prognosis. The identification of genetic alterations that drive this aggressive phenotype could aid in the development of more effective targeted therapies. In this study we aimed to pinpoint unique copy number alterations in sarcomatoid renal cell carcinoma compared to classical renal cell carcinoma subtypes. MATERIALS AND METHODS: Genomic copy number analysis was performed using single nucleotide polymorphism based microarrays on tissue extracted from the tumors of 81 patients who underwent renal mass excision, including 17 with sarcomatoid renal cell carcinoma. RESULTS: Sarcomatoid renal cell carcinoma showed a significantly higher number of copy number alterations than clear cell, papillary and chromophobe renal cell carcinoma (mean 18.0 vs 5.8, 6.5 and 7.2, respectively, p <0.0001). Copy number losses of chromosome arms 9q, 15q, 18p/q and 22q, and gains of 1q and 8q occurred in a significantly higher proportion of sarcomatoid renal cell carcinomas than in the other 3 histologies. Patients with sarcomatoid renal cell carcinoma demonstrated significantly worse overall survival compared to those without that condition on Kaplan-Meier analysis (p = 0.0001). Patients with 9 or more copy number alterations also demonstrated significantly worse overall survival than those with fewer than 9 copy number alterations (p = 0.004). CONCLUSIONS: Sarcomatoid changes in renal cell carcinoma are associated with a high rate of chromosomal imbalances with losses of 9q, 15q, 18p/q and 22q, and gains of 1q and 8q occurring at significantly higher frequencies in comparison to nonsarcomatoid renal cell carcinoma. Identifying candidate driver genes or tumor suppressor loci in these chromosomal regions may help identify targets for future therapies.
PURPOSE:Sarcomatoid changes in renal cell carcinoma are associated with a poor prognosis. The identification of genetic alterations that drive this aggressive phenotype could aid in the development of more effective targeted therapies. In this study we aimed to pinpoint unique copy number alterations in sarcomatoid renal cell carcinoma compared to classical renal cell carcinoma subtypes. MATERIALS AND METHODS: Genomic copy number analysis was performed using single nucleotide polymorphism based microarrays on tissue extracted from the tumors of 81 patients who underwent renal mass excision, including 17 with sarcomatoid renal cell carcinoma. RESULTS:Sarcomatoid renal cell carcinoma showed a significantly higher number of copy number alterations than clear cell, papillary and chromophobe renal cell carcinoma (mean 18.0 vs 5.8, 6.5 and 7.2, respectively, p <0.0001). Copy number losses of chromosome arms 9q, 15q, 18p/q and 22q, and gains of 1q and 8q occurred in a significantly higher proportion of sarcomatoid renal cell carcinomas than in the other 3 histologies. Patients with sarcomatoid renal cell carcinoma demonstrated significantly worse overall survival compared to those without that condition on Kaplan-Meier analysis (p = 0.0001). Patients with 9 or more copy number alterations also demonstrated significantly worse overall survival than those with fewer than 9 copy number alterations (p = 0.004). CONCLUSIONS:Sarcomatoid changes in renal cell carcinoma are associated with a high rate of chromosomal imbalances with losses of 9q, 15q, 18p/q and 22q, and gains of 1q and 8q occurring at significantly higher frequencies in comparison to nonsarcomatoid renal cell carcinoma. Identifying candidate driver genes or tumor suppressor loci in these chromosomal regions may help identify targets for future therapies.
Authors: Caleb F Davis; Christopher J Ricketts; Min Wang; Lixing Yang; Andrew D Cherniack; Hui Shen; Christian Buhay; Hyojin Kang; Sang Cheol Kim; Catherine C Fahey; Kathryn E Hacker; Gyan Bhanot; Dmitry A Gordenin; Andy Chu; Preethi H Gunaratne; Michael Biehl; Sahil Seth; Benny A Kaipparettu; Christopher A Bristow; Lawrence A Donehower; Eric M Wallen; Angela B Smith; Satish K Tickoo; Pheroze Tamboli; Victor Reuter; Laura S Schmidt; James J Hsieh; Toni K Choueiri; A Ari Hakimi; Lynda Chin; Matthew Meyerson; Raju Kucherlapati; Woong-Yang Park; A Gordon Robertson; Peter W Laird; Elizabeth P Henske; David J Kwiatkowski; Peter J Park; Margaret Morgan; Brian Shuch; Donna Muzny; David A Wheeler; W Marston Linehan; Richard A Gibbs; W Kimryn Rathmell; Chad J Creighton Journal: Cancer Cell Date: 2014-08-21 Impact factor: 31.743
Authors: J Gronwald; S Störkel; H Holtgreve-Grez; P Hadaczek; C Brinkschmidt; A Jauch; J Lubinski; T Cremer Journal: Cancer Res Date: 1997-02-01 Impact factor: 12.701
Authors: Viviane Gnemmi; Audrey Bouillez; Kelly Gaudelot; Brigitte Hémon; Bélinda Ringot; Nicolas Pottier; François Glowacki; Arnauld Villers; David Vindrieux; Christelle Cauffiez; Isabelle Van Seuningen; David Bernard; Xavier Leroy; Sébastien Aubert; Michaël Perrais Journal: Cancer Lett Date: 2013-12-30 Impact factor: 8.679
Authors: Jianming Pei; Madelyn M Feder; Tahseen Al-Saleem; Zemin Liu; Angen Liu; Gary R Hudes; Robert G Uzzo; Joseph R Testa Journal: Genes Chromosomes Cancer Date: 2010-07 Impact factor: 5.006
Authors: F Jiang; H Moch; J Richter; C Egenter; T Gasser; L Bubendorf; R Gschwind; G Sauter; M J Mihatsch Journal: J Pathol Date: 1998-08 Impact factor: 7.996
Authors: L E Moore; E Jaeger; M L Nickerson; P Brennan; S De Vries; R Roy; J Toro; H Li; S Karami; P Lenz; D Zaridze; V Janout; V Bencko; M Navratilova; N Szeszenia-Dabrowska; D Mates; W M Linehan; M Merino; J Simko; R Pfeiffer; P Boffetta; S Hewitt; N Rothman; W-H Chow; F M Waldman Journal: Oncogenesis Date: 2012-06-25 Impact factor: 7.485
Authors: F Cornelis; D Ambrosetti; L Rocher; L E Derchi; B Renard; P Puech; M Claudon; O Rouvière; S Ferlicot; C Roy; M Yacoub; N Grenier; J C Bernhard Journal: Eur Radiol Date: 2016-06-22 Impact factor: 5.315
Authors: Andres F Correa; Karen J Ruth; Tahseen Al-Saleem; Jianming Pei; Essel Dulaimi; Debra Kister; Michelle Collins; Phillip H Abbosh; Michael J Slifker; Eric Ross; Robert G Uzzo; Joseph R Testa Journal: Cancer Biol Ther Date: 2020-03-01 Impact factor: 4.742
Authors: Nirmish Singla; Zhiqun Xie; Ze Zhang; Ming Gao; Qurratulain Yousuf; Oreoluwa Onabolu; Tiffani McKenzie; Vanina Toffessi Tcheuyap; Yuanqing Ma; Jacob Choi; Renee McKay; Alana Christie; Oscar Reig Torras; Isaac A Bowman; Vitaly Margulis; Ivan Pedrosa; Christopher Przybycin; Tao Wang; Payal Kapur; Brian Rini; James Brugarolas Journal: JCI Insight Date: 2020-04-09
Authors: Samra Turajlic; Hang Xu; Kevin Litchfield; Andrew Rowan; Stuart Horswell; Tim Chambers; Tim O'Brien; Jose I Lopez; Thomas B K Watkins; David Nicol; Mark Stares; Ben Challacombe; Steve Hazell; Ashish Chandra; Thomas J Mitchell; Lewis Au; Claudia Eichler-Jonsson; Faiz Jabbar; Aspasia Soultati; Simon Chowdhury; Sarah Rudman; Joanna Lynch; Archana Fernando; Gordon Stamp; Emma Nye; Aengus Stewart; Wei Xing; Jonathan C Smith; Mickael Escudero; Adam Huffman; Nik Matthews; Greg Elgar; Ben Phillimore; Marta Costa; Sharmin Begum; Sophia Ward; Max Salm; Stefan Boeing; Rosalie Fisher; Lavinia Spain; Carolina Navas; Eva Grönroos; Sebastijan Hobor; Sarkhara Sharma; Ismaeel Aurangzeb; Sharanpreet Lall; Alexander Polson; Mary Varia; Catherine Horsfield; Nicos Fotiadis; Lisa Pickering; Roland F Schwarz; Bruno Silva; Javier Herrero; Nick M Luscombe; Mariam Jamal-Hanjani; Rachel Rosenthal; Nicolai J Birkbak; Gareth A Wilson; Orsolya Pipek; Dezso Ribli; Marcin Krzystanek; Istvan Csabai; Zoltan Szallasi; Martin Gore; Nicholas McGranahan; Peter Van Loo; Peter Campbell; James Larkin; Charles Swanton Journal: Cell Date: 2018-04-12 Impact factor: 41.582